Victoza solution for s/c injection Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

victoza solution for s/c injection

novo nordisk a/s - liraglutide - solution for s/c injection - 6mg/ml

BYDUREON POLVO Y DISOLVENTE PARA SUSPENSIÓN INYECTABLE DE LIBERACIÓN PROLONGADA EN PLUMA PRELLENADA. Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

bydureon polvo y disolvente para suspensión inyectable de liberación prolongada en pluma prellenada.

astrazeneca camcar, s.a. - exenatide - exenatide....2,00 mg

BYETTA 5 ug INJECTION South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

byetta 5 ug injection

astrazeneca pharmaceuticals (pty) ltd - injection - see ingredients - each dose contains exenatide 5,0 ug

BYETTA 10 ug INJECTION South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

byetta 10 ug injection

astrazeneca pharmaceuticals (pty) ltd - injection - see ingredients - each dose contains exenatide 10,0 ug

BYDUREON BCISE INJECTION South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

bydureon bcise injection

astrazeneca pharmaceuticals (pty) ltd - injection - 2,0 mg - each dose (0,85 ml) contains exenatide 2,0 mg

Saxenda New Zealand - English - Medsafe (Medicines Safety Authority)

saxenda

novo nordisk pharmaceuticals ltd - liraglutide 6 mg/ml;   - solution for injection - 6 mg/ml - active: liraglutide 6 mg/ml   excipient: dibasic sodium phosphate dihydrate hydrochloric acid phenol propylene glycol sodium hydroxide water for injection - saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (bmi) of · 30 kg/m2 or greater (obese) or · 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia, or obstructive sleep apnoea. treatment with saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if a patient has not lost at least 5% of their initial body weight.

Trulicity 0.75mg solution for injection in pre-filled pen Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

trulicity 0.75mg solution for injection in pre-filled pen

zuellig pharma sdn bhd - dulaglutide -

Saxenda 6mgml Solution for Injection in Pre-filled Pen Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

saxenda 6mgml solution for injection in pre-filled pen

novo nordisk pharma (malaysia) sdn. bhd. - liraglutide -

Soliqua SoloStar 100unitsmL+33mcgmL solution for injection in a pre-filled pen Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

soliqua solostar 100unitsml+33mcgml solution for injection in a pre-filled pen

sanofi-aventis (malaysia) sdn. bhd. - insulin glargine; lixisenatide -

Soliqua SoloStar 100unitsmL+50mcgmL solution for injection in a pre-filled pen Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

soliqua solostar 100unitsml+50mcgml solution for injection in a pre-filled pen

sanofi-aventis (malaysia) sdn. bhd. - insulin glargine; lixisenatide -